Informations générales (source: ClinicalTrials.gov)
Clozapine and Haematologic Malignancies: an Observational and Retrospective Study Using the WHO Pharmacovigilance Database (CLOZARIX)
Observational
University Hospital, Caen (Voir sur ClinicalTrials)
mars 2019
août 2024
03 août 2024
Clozapine may lead to various adverse reactions, including neutropenia and
agranulocytosis. This study investigates reports of lymphoma and leukaemias for clozapine
in the World Health Organization's (WHO) global database of individual safety case
reports (VigiBase).
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Caen University Hospital, Department of Pharmacology - 14033 - Caen - Normandie - France | Basile Chrétien, PharmD, MSc | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Case reported in the World Health Organization (WHO) database of individual safety
case reports to 03/05/2019
- Adverse events reported were including the MedDRA terms: Malignant Lymphoma (SMQ),
Leukaemia (HLGT)
- Patients treated with at least one liable antipsychotic drug (ATC class N05A)
- Case reported in the World Health Organization (WHO) database of individual safety
case reports to 03/05/2019
- Adverse events reported were including the MedDRA terms: Malignant Lymphoma (SMQ),
Leukaemia (HLGT)
- Patients treated with at least one liable antipsychotic drug (ATC class N05A)
- Chronology not compatible between the drug and the toxicity